Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CVRx, Inc. incurred term loan of $10 million with Innovatus Life Sciences Fund I, LP at prime rate plus 2.65% maturing May 9, 2031.
- Instrument
- term loan
- Principal
- $10 million
- Counterparty
- Innovatus Life Sciences Fund I, LP
- Rate
- prime rate plus 2.65%
- Maturity
- May 9, 2031
- Event
- incurrence
Exact text from the filing
revenue exceeds $100 million. The term loans continue to be secured by substantially all of the Company’s assets. Also on the Closing Date, the Company borrowed an additional $10 million under the Loan Agreement, bringing the total outstanding principal amount of term loans to $60 million. The Company has the option to draw (i) $15 million between June 1, 2027
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CVRx, Inc. amended credit facility of $50 million with Innovatus Life Sciences Fund I, LP at floating rate per annum equal to the sum of (i) the greater of (A) the prime rat maturing May 9, 2031.
- Instrument
- credit facility
- Principal
- $50 million
- Counterparty
- Innovatus Life Sciences Fund I, LP
- Rate
- floating rate per annum equal to the sum of (i) the greater of (A) the prime rat
- Maturity
- May 9, 2031
- Event
- amendment
Exact text from the filing
Pursuant to the Amendment, (a) the terms loans available to the Company are increased by $50 million, to an aggregate principal amount of up to $100 million
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CVRx, Inc. amended Amendment with Innovatus Life Sciences Fund I, LP valued at $50 million (effective 2026-01-09).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Innovatus Life Sciences Fund I, LP
- Value
- $50 million
- Effective
- 2026-01-09
Exact text from the filing
On January 9, 2026 (the “Closing Date”), CVRx, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its existing Loan and Security Agreement dated October 31, 2022, as previously amended on March 13, 2023 (as amended, the “Loan Agreement”), among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto.
View on SEC.gov